Nurix Therapeutics (NRIX) RBC Capital Markets Global Healthcare Conference 2026 summary

Advances in BTK degradation and clinical progress

• BTK degraders show expanding advantages in CLL, addressing all resistance mutations and demonstrating high response rates, including 83% objective response in heavily pretreated patients.

• Degradation removes both kinase and scaffolding functions of BTK, overcoming mechanisms untouchable by inhibitors and leading to durable responses with a favorable safety profile.

• Long-term data show progression-free survival of 22.1 months in advanced patients, with consistent efficacy and safety across expanding cohorts.

Upcoming data and competitive positioning

• Detailed new data on bexobrutideg will be presented at EHA, focusing on consistency and durability in new phase Ib cohorts, including first-line patients.

• Bexobrutideg is emerging as best-in-class among BTK degraders, with superior selectivity, potency, and safety compared to competitors and inhibitors.

• Degraders are positioned to potentially displace inhibitors as the preferred approach in CLL.

Clinical development and trial execution

• Phase II pivotal study in late-line CLL is ongoing, targeting 100 patients for potential accelerated approval, with enrollment completion expected this year.

• Phase III DAYBreak CLL-306 trial will launch mid-year, comparing bexobrutideg head-to-head with pirtobrutinib in second-line patients, aiming for global enrollment at 200 sites.

• The trial is designed as a superiority study, leveraging pirtobrutinib as the most recently approved comparator.